Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18205
Country/Region: Kenya
Year: 2018
Main Partner: University of Maryland
Main Partner Program: University of Maryland Baltimore
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $6,364,493 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $264,456
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $167,067
Testing: HIV Testing and Counseling (HVCT) $566,621
Sexual Prevention: Other Sexual Prevention (HVOP) $1,872,136
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $417,669
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $328,961
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $2,672,884
Treatment: Pediatric Treatment (PDTX) $74,699
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 147
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 147
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 147
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2019 147
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 442
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 443
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 146
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 152
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 1,464
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 1,469
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 149
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 152
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 2,057
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 2,056
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 150
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2019 149
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 442
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 440
GEND_GBV 25-29, Male, Physical and/or Emotional Violence 2019 150
GEND_GBV 25-29, Male, Sexual Violence (Post-Rape Care) 2019 149
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 392
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 440
GEND_GBV 30-34, Male, Physical and/or Emotional Violence 2019 150
GEND_GBV 30-34, Male, Sexual Violence (Post-Rape Care) 2019 149
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 442
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 440
GEND_GBV 35-39, Male, Physical and/or Emotional Violence 2019 150
GEND_GBV 35-39, Male, Sexual Violence (Post-Rape Care) 2019 149
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 442
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 440
GEND_GBV 40-49, Male, Physical and/or Emotional Violence 2019 150
GEND_GBV 40-49, Male, Sexual Violence (Post-Rape Care) 2019 149
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 151
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2019 149
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2019 146
GEND_GBV 50+, Male, Sexual Violence (Post-Rape Care) 2019 150
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 1,814
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 7,341
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 7,344
GEND_GBV Number of people receiving post-GBV care 2019 14,687
HTS_SELF 2019 82,554
HTS_SELF 15-19, Female, Directly-Assisted 2019 4,422
HTS_SELF 15-19, Female, Unassisted 2019 4,422
HTS_SELF 15-19, Male, Directly-Assisted 2019 1,474
HTS_SELF 15-19, Male, Unassisted 2019 1,474
HTS_SELF 20-24, Female, Directly-Assisted 2019 4,422
HTS_SELF 20-24, Female, Unassisted 2019 4,422
HTS_SELF 20-24, Male, Directly-Assisted 2019 1,474
HTS_SELF 20-24, Male, Unassisted 2019 1,474
HTS_SELF 25-29, Female, Directly-Assisted 2019 4,422
HTS_SELF 25-29, Female, Unassisted 2019 4,422
HTS_SELF 25-29, Male, Directly-Assisted 2019 1,474
HTS_SELF 25-29, Male, Unassisted 2019 1,474
HTS_SELF 30-34, Female, Directly-Assisted 2019 4,422
HTS_SELF 30-34, Female, Unassisted 2019 4,422
HTS_SELF 30-34, Male, Directly-Assisted 2019 1,474
HTS_SELF 30-34, Male, Unassisted 2019 1,474
HTS_SELF 35-39, Female, Directly-Assisted 2019 4,422
HTS_SELF 35-39, Female, Unassisted 2019 4,422
HTS_SELF 35-39, Male, Directly-Assisted 2019 1,474
HTS_SELF 35-39, Male, Unassisted 2019 1,474
HTS_SELF 40-49, Female, Directly-Assisted 2019 4,422
HTS_SELF 40-49, Female, Unassisted 2019 4,422
HTS_SELF 40-49, Male, Directly-Assisted 2019 1,474
HTS_SELF 40-49, Male, Unassisted 2019 1,474
HTS_SELF 50+, Female, Directly-Assisted 2019 4,422
HTS_SELF 50+, Female, Unassisted 2019 4,422
HTS_SELF 50+, Male, Directly-Assisted 2019 1,474
HTS_SELF 50+, Male, Unassisted 2019 1,474
HTS_SELF Directly-Assisted 2019 41,277
HTS_SELF FSW, Directly-Assisted 2019 55,311
HTS_SELF MSM, Directly-Assisted 2019 12,383
HTS_SELF PWID, Directly-Assisted 2019 4,953
HTS_SELF Unassisted 2019 41,277
HTS_SELF Unassisted - Other 2019 4,128
HTS_SELF Unassisted - Self 2019 20,638
HTS_SELF Unassisted - Sex Partner 2019 16,511
HTS_TST 15-19, Female, Negative 2019 90
HTS_TST 15-19, Male, Negative 2019 43
HTS_TST 20-24, Female, Negative 2019 317
HTS_TST 20-24, Male, Negative 2019 139
HTS_TST 25-29, Female, Negative 2019 670
HTS_TST 25-29, Female, Negative 2019 26
HTS_TST 25-29, Female, Negative 2019 72
HTS_TST 25-29, Female, Negative 2019 4,461
HTS_TST 25-29, Female, Negative 2019 4,389
HTS_TST 25-29, Female, Negative 2019 17
HTS_TST 25-29, Female, Negative 2019 23
HTS_TST 25-29, Male, Negative 2019 1,402
HTS_TST 25-29, Male, Negative 2019 561
HTS_TST 25-29, Male, Negative 2019 50
HTS_TST 25-29, Male, Negative 2019 152
HTS_TST 25-29, Male, Negative 2019 9,352
HTS_TST 25-29, Male, Negative 2019 38
HTS_TST 25-29, Male, Negative 2019 27
HTS_TST 30-34, Female, Negative 2019 766
HTS_TST 30-34, Female, Negative 2019 28
HTS_TST 30-34, Female, Negative 2019 83
HTS_TST 30-34, Female, Negative 2019 5,098
HTS_TST 30-34, Female, Negative 2019 4,389
HTS_TST 30-34, Female, Negative 2019 20
HTS_TST 30-34, Female, Negative 2019 19
HTS_TST 30-34, Male, Negative 2019 1,685
HTS_TST 30-34, Male, Negative 2019 63
HTS_TST 30-34, Male, Negative 2019 182
HTS_TST 30-34, Male, Negative 2019 11,218
HTS_TST 30-34, Male, Negative 2019 46
HTS_TST 30-34, Male, Negative 2019 31
HTS_TST 35-39, Female, Negative 2019 190
HTS_TST 35-39, Female, Negative 2019 8
HTS_TST 35-39, Female, Negative 2019 21
HTS_TST 35-39, Female, Negative 2019 1,278
HTS_TST 35-39, Female, Negative 2019 4,389
HTS_TST 35-39, Female, Negative 2019 24
HTS_TST 35-39, Male, Negative 2019 1,685
HTS_TST 35-39, Male, Negative 2019 63
HTS_TST 35-39, Male, Negative 2019 182
HTS_TST 35-39, Male, Negative 2019 11,218
HTS_TST 35-39, Male, Negative 2019 46
HTS_TST 35-39, Male, Negative 2019 43
HTS_TST 40-49, Female, Negative 2019 190
HTS_TST 40-49, Female, Negative 2019 8
HTS_TST 40-49, Female, Negative 2019 21
HTS_TST 40-49, Female, Negative 2019 1,278
HTS_TST 40-49, Female, Negative 2019 4,389
HTS_TST 40-49, Female, Negative 2019 19
HTS_TST 40-49, Male, Negative 2019 35
HTS_TST 40-49, Male, Negative 2019 560
HTS_TST 40-49, Male, Negative 2019 20
HTS_TST 40-49, Male, Negative 2019 61
HTS_TST 40-49, Male, Negative 2019 3,735
HTS_TST 40-49, Male, Negative 2019 16
HTS_TST 50+, Male, Negative 2019 2
HTS_TST By Key Population: FSW, Negative 2019 10,510
HTS_TST By Key Population: MSM, Negative 2019 1,319
HTS_TST By Key Population: PWID, Negative 2019 3,254
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 264,475
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 20
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 2,394
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 10,652
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 2
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 101
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 277
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 66
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 54
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 118
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 55
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 402
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 393
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 3
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 10
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 349
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 166
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 1,202
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 532
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 10
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 30
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 1,248
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 301
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 252
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 15,863
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 15,920
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 74,160
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 32,809
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 636
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 1,869
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 1,001
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 12
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 14
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 13
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 22
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 26
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 22
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 27
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 17
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 30
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2019 31
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 83
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 19
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 16
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 3,231
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 1,539
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 11,134
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 4,924
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 96
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 279
HTS_TST Service Delivery Point (Facility) VMMC: 10-14, Negative 2019 561
HTS_TST Service Delivery Point (Facility) VMMC: 15-19, Negative 2019 841
HTS_TST Service Delivery Point (Facility) VMMC: 20-24, Negative 2019 841
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 460
HTS_TST_POS 20-24, Female, Positive 2019 2
HTS_TST_POS 20-24, Male, Positive 2019 2
HTS_TST_POS 25-29, Female, Positive 2019 11
HTS_TST_POS 25-29, Female, Positive 2019 7
HTS_TST_POS 25-29, Female, Positive 2019 61
HTS_TST_POS 25-29, Female, Positive 2019 452
HTS_TST_POS 25-29, Female, Positive 2019 10
HTS_TST_POS 25-29, Male, Positive 2019 24
HTS_TST_POS 25-29, Male, Positive 2019 15
HTS_TST_POS 25-29, Male, Positive 2019 12
HTS_TST_POS 25-29, Male, Positive 2019 1
HTS_TST_POS 25-29, Male, Positive 2019 128
HTS_TST_POS 25-29, Male, Positive 2019 12
HTS_TST_POS 30-34, Female, Positive 2019 16
HTS_TST_POS 30-34, Female, Positive 2019 8
HTS_TST_POS 30-34, Female, Positive 2019 68
HTS_TST_POS 30-34, Female, Positive 2019 10
HTS_TST_POS 30-34, Male, Positive 2019 31
HTS_TST_POS 30-34, Male, Positive 2019 20
HTS_TST_POS 30-34, Male, Positive 2019 1
HTS_TST_POS 30-34, Male, Positive 2019 154
HTS_TST_POS 30-34, Male, Positive 2019 15
HTS_TST_POS 35-39, Female, Positive 2019 3
HTS_TST_POS 35-39, Female, Positive 2019 3
HTS_TST_POS 35-39, Female, Positive 2019 19
HTS_TST_POS 35-39, Female, Positive 2019 10
HTS_TST_POS 35-39, Male, Positive 2019 31
HTS_TST_POS 35-39, Male, Positive 2019 20
HTS_TST_POS 35-39, Male, Positive 2019 1
HTS_TST_POS 35-39, Male, Positive 2019 154
HTS_TST_POS 35-39, Male, Positive 2019 22
HTS_TST_POS 40-49, Female, Positive 2019 3
HTS_TST_POS 40-49, Female, Positive 2019 3
HTS_TST_POS 40-49, Female, Positive 2019 19
HTS_TST_POS 40-49, Female, Positive 2019 10
HTS_TST_POS 40-49, Male, Positive 2019 18
HTS_TST_POS 40-49, Male, Positive 2019 11
HTS_TST_POS 40-49, Male, Positive 2019 8
HTS_TST_POS 40-49, Male, Positive 2019 51
HTS_TST_POS By Key Population: FSW, Positive 2019 565
HTS_TST_POS By Key Population: MSM, Positive 2019 224
HTS_TST_POS By Key Population: PWID, Positive 2019 60
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 30
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 213
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 34
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 16
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 113
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 54
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 210
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 216
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 1,002
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 446
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 22
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 60
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 28
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 205
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 91
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) VMMC: 10-14, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) VMMC: 15-19, Positive 2019 22
HTS_TST_POS Service Delivery Point (Facility) VMMC: 20-24, Positive 2019 22
KP_MAT Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months 2019 2,400
KP_MAT Sex: Female 2019 1,000
KP_MAT Sex: Male 2019 1,400
KP_MAT Sum of Sex disaggregates 2019 2,400
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 42,164
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 682
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 7,117
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 432
KP_PREV By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 3,727
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 54,122
PMTCT_ART Already on ART at beginning of current pregnancy 2019 1,018
PMTCT_ART New on ART 2019 665
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 1,683
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 32,180
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 32
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 32
PMTCT_EID Sum of Infant Age disaggregates 2019 32
PMTCT_STAT 25-29, Female 2019 4,675
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 209
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 4,365
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 97
PMTCT_STAT 30-34, Female 2019 4,630
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 209
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 4,365
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 97
PMTCT_STAT 35-39, Female 2019 4,675
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 209
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 4,365
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 97
PMTCT_STAT 40-49, Female 2019 4,675
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 209
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 4,365
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 97
PMTCT_STAT By Age (Numerator): 10-14 2019 23
PMTCT_STAT By Age (Numerator): 15-19 2019 2,464
PMTCT_STAT By Age (Numerator): 20-24 2019 11,036
PMTCT_STAT By Age (Numerator): 50+ 2019 2
PMTCT_STAT By Number of known positives: 15-19 2019 30
PMTCT_STAT By Number of known positives: 20-24 2019 193
PMTCT_STAT By Number of new negative: 10-14 2019 20
PMTCT_STAT By Number of new negative: 15-19 2019 2,380
PMTCT_STAT By Number of new negative: 20-24 2019 10,580
PMTCT_STAT By Number of new negative: 50+ 2019 2
PMTCT_STAT By Number of new positives: 15-19 2019 51
PMTCT_STAT By Number of new positives: 20-24 2019 240
PMTCT_STAT Number of new ANC and L&D clients 2019 32,691
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 32,180
PMTCT_STAT_den 25-29, Female 2019 4,728
PMTCT_STAT_den 30-34, Female 2019 4,728
PMTCT_STAT_den 35-39, Female 2019 4,728
PMTCT_STAT_den 40-49, Female 2019 4,728
PMTCT_STAT_den By Age (Denominator): <15-19 2019 2,741
PMTCT_STAT_den By Age (Denominator): 10-14 2019 18
PMTCT_STAT_den By Age (Denominator): 20-24 2019 11,020
PrEP_NEW 25-29, Female 2019 44
PrEP_NEW 25-29, Male 2019 19
PrEP_NEW 30-34, Female 2019 32
PrEP_NEW 30-34, Male 2019 25
PrEP_NEW 35-39, Female 2019 31
PrEP_NEW 35-39, Male 2019 25
PrEP_NEW 40-49, Female 2019 31
PrEP_NEW 40-49, Male 2019 19
PrEP_NEW Female 15-19 2019 75
PrEP_NEW Female 20-24 2019 256
PrEP_NEW Female 50+ 2019 12
PrEP_NEW FSW 2019 87
PrEP_NEW Male 15-19 2019 6
PrEP_NEW Male 20-24 2019 37
PrEP_NEW Male 50+ 2019 12
PrEP_NEW MSM 2019 44
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 624
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 247
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 321
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 568
TB_PREV By Age/Sex (Numerator): <15, Female 2019 85
TB_PREV By Age/Sex (Numerator): <15, Male 2019 98
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 1,585
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 895
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 2,663
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 3,131
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 108
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 118
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 1,858
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 1,047
TB_PREV_den IPT, Life-long ART, New, Positive 2019 3,131
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 57
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 705
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 69
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,049
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 1,880
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 1,877
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 66
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 694
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 69
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,048
TX_CURR 25-29, Female, Positive 2019 4,240
TX_CURR 25-29, Male, Positive 2019 1,322
TX_CURR 30-34, Female, Positive 2019 3,217
TX_CURR 30-34, Male, Positive 2019 2,065
TX_CURR 35-39, Female, Positive 2019 3,217
TX_CURR 35-39, Male, Positive 2019 2,065
TX_CURR 40-49, Female, Positive 2019 2,193
TX_CURR 40-49, Male, Positive 2019 2,065
TX_CURR Age/Sex: <1 2019 15
TX_CURR Age/Sex: <1-9 2019 476
TX_CURR Age/Sex: 10-14 Female 2019 250
TX_CURR Age/Sex: 10-14 Male 2019 243
TX_CURR Age/Sex: 15-19 Female 2019 673
TX_CURR Age/Sex: 15-19 Male 2019 365
TX_CURR Age/Sex: 20-24 Female 2019 1,880
TX_CURR Age/Sex: 20-24 Male 2019 484
TX_CURR Age/Sex: 50+ Female 2019 1,755
TX_CURR Age/Sex: 50+ Male 2019 745
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 27,270
TX_CURR Sum of age/sex disaggregates 2019 1,038
TX_NEW 25-29, Female, Positive 2019 143
TX_NEW 25-29, Male, Positive 2019 259
TX_NEW 30-34, Female, Positive 2019 159
TX_NEW 30-34, Male, Positive 2019 310
TX_NEW 35-39, Female, Positive 2019 42
TX_NEW 35-39, Male, Positive 2019 310
TX_NEW 40-49, Female, Positive 2019 42
TX_NEW 40-49, Male, Positive 2019 103
TX_NEW Breastfeeding status 2019 36
TX_NEW By Age/Sex: <1 2019 51
TX_NEW By Age/Sex: 1-9 2019 24
TX_NEW By Age/Sex: 10-14 Female 2019 5
TX_NEW By Age/Sex: 10-14 Male 2019 7
TX_NEW By Age/Sex: 15-19 Female 2019 509
TX_NEW By Age/Sex: 15-19 Male 2019 191
TX_NEW By Age/Sex: 20-24 Female 2019 1,746
TX_NEW By Age/Sex: 20-24 Male 2019 585
TX_NEW By Age/Sex: 50+ Female 2019 13
TX_NEW By Age/Sex: 50+ Male 2019 54
TX_NEW FSW 2019 106
TX_NEW MSM 2019 48
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 4,561
TX_NEW Pregnancy status 2019 550
TX_NEW Sum of Age/Sex disaggregates 2019 3,110
TX_NEW TG 2019 10
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 26,472
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 463
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 24
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 445
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 23
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 15,838
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 835
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 8,402
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 442
TX_PVLS_den Denominator: Indication: Routine 2019 25,149
TX_PVLS_den Denominator: Indication: Targeted 2019 1,323
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 126
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 57
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 5,109
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 2,319
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 7,610
TX_RET Numerator by Status: Breastfeeding 2019 144
TX_RET Numerator by Status: Pregnant 2019 692
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 8,196
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 122
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 57
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 5,519
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 2,500
TX_RET_den Denominator by Status: Breastfeeding 2019 144
TX_RET_den Denominator by Status: Pregnant 2019 692
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 27,270
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 550
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 434
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 17,174
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 9,116
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 593
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 270
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 891
Cross Cutting Budget Categories and Known Amounts Total: $1,882,152
Gender: Gender Based Violence (GBV) $17,500
GBV Prevention
Implementation
Capacity building
Post GBV Care
Implementation
Capacity building
Gender: Gender Equality $127,400
Equity in HIV prevention, care, treatment and support
Implementation
Capacity building
Renovation $12,871
Human Resources for Health $1,657,197
Motor Vehicles: Purchased $67,184